Mather Group’s Anika Therapeutics ANIK Stock Holding History

Mather Group’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100	Closed	-$940	–	688
2025 Q3	$940	Buy	+100	New	+$955	﹤0.01%	1591
2025 Q2	–	Sell	-100	Closed	-$1.5K	–	658
2025 Q1	$1.5K	Buy	+100	New	+$1.66K	﹤0.01%	1604

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mather Group's ANIK Position: Q4 2025 in Review

Mather Group sold out of Anika Therapeutics (ANIK) in Q4 2025, closing a stake of 100 shares — an estimated $940 sold.

Mather Group first reported a position in ANIK in Q1 2025 and held it in 2 quarters. The position peaked at $1.5K in Q1 2025. 126 funds tracked by Wall St. Rank hold ANIK as of Q4 2025.

Mather Group reported no remaining Anika Therapeutics position as of Q4 2025 after selling out during the quarter.
Mather Group sold 100 Anika Therapeutics shares in Q4 2025, an estimated $940.
Mather Group first reported a position in Anika Therapeutics in Q1 2025 and held it in 2 quarters.
Mather Group's Anika Therapeutics position peaked at $1.5K in Q1 2025.
126 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2025.

Based on Mather Group's 13F filing for Q4 2025, filed 13 Jan 2026.